Walter V. Klemp - Jun 16, 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power of Attorney
Stock symbol
MBRX
Transactions as of
Jun 16, 2023
Transactions value $
-$3,470
Form type
4
Date filed
6/20/2023, 06:00 PM
Previous filing
Nov 28, 2022
Next filing
Jun 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +25K +6.1% 435K Jun 16, 2023 Direct F1
transaction MBRX Common Stock Tax liability -$3.47K -6.09K -1.4% $0.57 429K Jun 16, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -25K -2.28% $0.00 1.07M Jun 16, 2023 Common Stock 25K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 16, 2021, the reporting person was granted 100,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.